Beta Blockers—Still the Best Option or an Obligation!

Abstract

Beta blockers (BBs) are widely acknowledged as a standard care for numerous cardiovascular conditions. They have a long-established history in treating angina, regulating heart rate in atrial fibrillation and ventricular tachycardia, and managing heart failure with reduced ejection fraction (HFREF). The effectiveness of BBs in treating acute coronary syndrome was established during a time when reperfusion therapies were not readily available. However, with the recent advancements in coronary revascularization techniques, the role of BB therapy in managing patients after a myocardial infarction and in those with stable angina has become a subject of debate. Likewise, there are uncertainties about the efficacy of BBs in individuals with HFREF who also suffer from atrial fibrillation, as well as in patients with heart failure with preserved ejection fraction (HFPEF). Furthermore, there are numerous concerns about using BBs as the initial therapy, as was customary in hypertension management in the past, and safety concerns regarding their use in patients undergoing non-cardiac surgery. This comprehensive review aims to thoroughly examine all existing recent evidence concerning BB therapy in various cardiovascular scenarios and to provide a valuable guidance to the clinicians in the field of cardiology.